Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Revenue
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
|
Revenue
¥5.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥12.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
¥10.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥28B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Revenue
¥2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥5.8B
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a prominent player in the global pharmaceutical landscape, carving its niche with a remarkable story of specialization and expansion. Founded in 1998, the company first made its mark as a leading producer of heparin sodium, a critical anticoagulant used worldwide to prevent and treat blood clots. Operating from Shenzhen, China, Hepalink has meticulously built an integrated production chain that spans from the procurement of raw materials to the sale of finished pharmaceutical products. The company sources raw heparin from porcine intestines, which it then processes into pharmaceutical-grade heparin and low molecular weight heparins (LMWHs), leveraging its proprietary purification and synthesis technologies. This robust vertical integration not only ensures quality control but also bolsters its competitive positioning in global markets, where it serves hospitals, pharmaceutical companies, and research institutions. Beyond its heparin-centric foundation, Hepalink has strategically expanded its portfolio through a series of calculated ventures and acquisitions aimed at broadening its business model and revenue streams. Over the years, it has diversified into contract development and manufacturing services (CDMO), biotechnology innovations, and the production of other complementary pharmaceutical products. Its acquisition strategies, such as the purchase of U.S.-based Cytovance Biologics, have been pivotal in gaining an international footprint and enriching its expertise in biologics. By investing in research and development, Hepalink continues to explore biologically derived treatments, aiming to lead in therapeutic areas like oncology and cardiology. This diversification effort not only mitigates the risks inherent in relying heavily on a single product line but also positions Hepalink as an agile and innovative player, ready to navigate the ever-evolving pharmaceutical industry landscape.
See Also
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Revenue?
Revenue
5.3B
CNY
Based on the financial report for Dec 31, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Revenue amounts to 5.3B CNY.
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
10%
Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been -6% over the past three years , 3% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet